Guidelines for the safe administration of high-dose interleukin-2

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• High-dose interleukin-2 (IL-2) demonstrates efficacy in treating metastatic melanoma and renal cell carcinoma.
• Objective clinical regression is observed in 15-17% of patients, with durable complete regression in 6-8%.

Purpose of the Study:

• To provide practical guidelines for the safe administration of high-dose IL-2.
• To consolidate clinical experience for optimizing IL-2 therapy.

Main Methods:

• Review of clinical experience with high-dose IL-2 administration.
• Development of practical guidelines based on observed side effects and management strategies.

Main Results:

• High-dose IL-2 is FDA-approved for metastatic melanoma and renal cell carcinoma.
• Established methods exist for safely managing IL-2 side effects.
• Guidelines focus on practical aspects of IL-2 administration.

Conclusions:

• High-dose IL-2 is a valuable treatment option for specific metastatic cancers.
• Safe administration is achievable through adherence to established protocols.
• Clinical expertise is key to maximizing IL-2 therapy benefits while minimizing risks.